The company is committed to the research, development, production and sales of high-end molecular imaging equipment, providing users with world-leading PET/SPECT/CT series products and services. The company has set up dual R&D centers in Hefei and Linyi, of which: the parent company, Anhui Maide Yinghua Imaging Technology Co., Ltd. is located in Hefei Silicon Valley of Anhui, a comprehensive national science center, mainly engaged in the research and development of core components of high-end medical devices; the wholly-owned subsidiary, Shandong Maide Yinghua Science and Technology Co. It is a national high-tech enterprise, Shandong Province “specialized, fine, special and new” enterprise, provincial high-quality brand, and a provincial enterprise and a technology research and development center.

The company adheres to the concept of “leading the market with science and technology, creating value by sharing”, insists on the independent research and development of the core components of the whole line of products, realizes the commercialization of PET/CT for small animals in 2014 to fill the blank in China, and creates “ultra-high sensitivity PET technology” in 2017 to realize sub-second PET technology for the first time, which is the first time to realize sub-second PET technology in Shandong Province. In 2017, we created the “ultra-high sensitivity PET technology”, which realized sub-second four-dimensional molecular imaging for the first time. In 2020, we will develop the world's highest resolution PET for small animals, and in 2022, we will launch PET/SPECT/CT tri-modal products with fully independent intellectual property rights, independently mastering the key technologies and production processes, and leading the world in terms of technology level, and applying for dozens of patents for inventions, which cover countries such as China, Japan, the United States, and the European Union. The company has applied dozens of invention patents, covering China, Japan, the United States, the European Union and other countries.

Ten years of combing wind and rain, and now more into a big view. The company has undertaken the major basic research project of Natural Science Foundation of Shandong Province-“Tri-modal Statistical Fusion Imaging System for PET/CT/FMI in Small Animals”, the key research and development program of Shandong Province-“Ultra-high sensitivity PET-based brain imaging in seconds”, and the key research and development program of Shandong Province-“Ultra-high sensitivity PET-based brain imaging in seconds”. Since 2015, the company has initiated and successfully held the “Linyi International Nuclear Medicine and Molecular Imaging Summit Forum” every year, with more than ten overseas academicians and presidents of more than ten national nuclear medicine societies attending the forum to give lectures and discuss cooperation. It has provided an international, high-level, multidisciplinary academic exchange platform for domestic and foreign colleagues engaged in nuclear medicine diagnosis, treatment and basic research of molecular imaging, and has generated good international influence.